Trial Profile

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FT 819 (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine
Indications Myositis; Systemic lupus erythematosus; Systemic scleroderma; Vasculitis
Focus Adverse reactions
Sponsors Fate Therapeutics

Most Recent Events

13 May 2026 According to a Fate Therapeutics media release, as of 5 May 2026, Nineteen SLE patients across the two regimens have been treated, Eight patients have been treated across SSc, IIM and AAV. And, Of these 27 patients, 8 have been treated in an outpatient setting.
11 May 2026 Results presented in a Fate Therapeutics Media Release.
04 May 2026 According to a Fate Therapeutics media release, data from this study will be featured at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting to be held in Boston, MA, May 11-15, 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com